UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORTPursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934Date of report (date of earliest event reported): July 15, 2004
VIVUS, INC
DELAWARE
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
COMMISSION FILE NUMBER: 023490
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION) 943136179
(I.R.S. EMPLOYER
IDENTIFICATION NO.)1172 CASTRO STREET
MOUNTAIN VIEW, CA
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES
94040
(ZIP CODE)
(650) 9345200
(REGISTRANTS TELEPHONE NUMBER, INCLUDING AREA CODE)
N/A
(FORMER NAME, FORMER ADDRESS AND FORMER FISCAL YEAR, IF CHANGED SINCE LAST REPORT)
Item 5. Other Events and Regulation FD Disclosure.
On July 14, 2004, the Registrant issued a press release announcing that data from a recently completed Phase 2 clinical trial demonstrated that ALISTA, our topical formulation of alprostadil for the treatment of female sexual arousal disorder (FSAD), significantly increased the percentage of satisfying sexual events in pre-menopausal women with FSAD when compared with placebo. The press release is attached as exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 7. Exhibits.
(c)
Exhibit
Number Description 99.1 Press Release dated July 14, 2004.2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: July 15, 2004
VIVUS, INC.
/s/ LARRY J. STRAUSS
Larry J. Strauss
Vice President and Chief Financial Officer
3
VIVUS, INC.
Exhibit Description 99.1 Press Release dated July 14, 2004.
INDEX TO EXHIBITS
The following exhibits are filed herewith:4